Lopez-Rodriguez Elena, Gay-Jordi Gemma, Knudsen Lars, Ochs Matthias, Serrano-Mollar Anna
Institute of Functional Anatomy, Charité - Universitaetsmedizin Berlin, Berlin, Germany.
Institute of Functional and Applied Anatomy, Hannover Medical School, Hannover, Germany.
Front Med (Lausanne). 2021 Feb 17;8:640020. doi: 10.3389/fmed.2021.640020. eCollection 2021.
Idiopathic pulmonary fibrosis (IPF) is a progressively and ultimately fatal lung disease. Previously it has been shown that intratracheal administration of alveolar epithelial type II cells (AE2C) in the animal model of bleomycin-induced pulmonary fibrosis is able to reverse fibrosis and restore surfactant protein levels. However, to date, it has not been evaluated whether these changes involve any improvement in alveolar dynamics. Consequently, the aim of the present work was to study lung physiology after AE2C transplantation at different time points during the development of injury and fibrosis. Lung fibrosis was induced by intratracheal instillation of bleomycin (4U/kg) in rat lungs. The animals were transplanted with AE2C (2.5 × 10 cells/animal) 3 or 7 days after bleomycin instillation. Assessments were done at day 7 and 14 after the induction of fibrosis to plot time dependent changes in lung physiology and mechanics. To assess the pressures and rates at which closed alveoli reopens invasive pulmonary tests using a small-animal mechanical ventilator (Flexivent®, Scireq, Canada) including de-recruitability tests and forced oscillation technique as well as quasi-static pressure volume loops were performed. Afterwards lungs were fixed by vascular perfusion and subjected to design-based stereological evaluation at light and electron microscopy level. AE2C delivered during the lung injury phase (3 days) of the disease are only able to slightly recover the volume of AE2C and volume fraction of LB in AE2C. However, it did not show either positive effects regarding ventilated alveolar surface nor any increase of lung compliance. On the other hand, when AE2C are delivered at the beginning of the fibrotic phase (7 days after bleomycin instillation), an increased ventilated alveolar surface to control levels and reduced septal wall thickness can be observed. Moreover, transplanted animals showed better lung performance, with increased inspiratory capacity and compliance. In addition, a detailed analysis of surfactant active forms [mainly tubular myelin, lamellar body (LB)-like structures and multilamellar vesicles (MLV)], showed an effective recovery during the pro-fibrotic phase due to the healthy AE2C transplantation. In conclusion, AE2C transplantation during fibrogenic phases of the disease improves lung performance, structure and surfactant ultrastructure in bleomycin-induced lung fibrosis.
特发性肺纤维化(IPF)是一种进行性且最终致命的肺部疾病。此前研究表明,在博来霉素诱导的肺纤维化动物模型中气管内给予II型肺泡上皮细胞(AE2C)能够逆转纤维化并恢复表面活性蛋白水平。然而,迄今为止,尚未评估这些变化是否涉及肺泡动力学的任何改善。因此,本研究的目的是在损伤和纤维化发展的不同时间点研究AE2C移植后的肺生理学。通过在大鼠肺内气管内滴注博来霉素(4U/kg)诱导肺纤维化。在博来霉素滴注后3天或7天给动物移植AE2C(2.5×10个细胞/动物)。在纤维化诱导后的第7天和第14天进行评估,以绘制肺生理学和力学随时间的变化。为了评估闭合肺泡重新开放的压力和速率,使用小动物机械通气机(Flexivent®,Scireq,加拿大)进行侵入性肺部测试,包括去复张测试、强迫振荡技术以及准静态压力容积环。之后通过血管灌注固定肺,并在光镜和电镜水平进行基于设计的体视学评估。在疾病的肺损伤阶段(3天)给予的AE2C仅能轻微恢复AE2C的体积和AE2C中LB的体积分数。然而,它在通气肺泡表面方面未显示出积极作用,肺顺应性也未增加。另一方面,当在纤维化阶段开始时(博来霉素滴注后7天)给予AE2C时,可以观察到通气肺泡表面增加至对照水平且间隔壁厚度减小。此外,移植动物表现出更好的肺功能,吸气能力和顺应性增加。此外,对表面活性剂活性形式[主要是管状髓鞘、板层小体(LB)样结构和多层囊泡(MLV)]的详细分析表明,由于健康的AE2C移植,在纤维化前期有有效的恢复。总之,在疾病的纤维化阶段进行AE2C移植可改善博来霉素诱导的肺纤维化中的肺功能、结构和表面活性剂超微结构。